Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P60891

UPID:
PRPS1_HUMAN

ALTERNATIVE NAMES:
PPRibP; Phosphoribosyl pyrophosphate synthase I

ALTERNATIVE UPACC:
P60891; B1ALA8; B2R6T7; B4DNL6; D3DUX6; P09329

BACKGROUND:
Ribose-phosphate pyrophosphokinase 1, with alternative names PPRibP and Phosphoribosyl pyrophosphate synthase I, is essential for nucleotide synthesis. It catalyzes the synthesis of PRPP, a precursor in the biosynthesis pathways of both purine and pyrimidine nucleotides, which are vital for cellular functions.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Ribose-phosphate pyrophosphokinase 1 could open doors to potential therapeutic strategies. Its involvement in diseases such as Phosphoribosylpyrophosphate synthetase superactivity, Charcot-Marie-Tooth disease, ARTS syndrome, and X-linked deafness highlights its significance in medical research and drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.